Olaparib
FDA-approved product (capsule, oral), marketed as Lynparza.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Cancer
- Neoplasm
- Ovarian cancer
- Ovarian carcinoma
- Ovarian neoplasm
- Pancreatic carcinoma
- Pancreatic neoplasm
- Prostate cancer
- Prostate carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Poly (adp-ribose) polymerase (parp) inhibitors
- FDA pharmacologic class
- Poly(ADP-Ribose) Polymerase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Olaparib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Clomipramine HydrochlorideExisting use: Depressive disorder, Major depressive disorder, Obsessive-compulsive disorder67.6% AI-predicted activityagainst M. tuberculosis33 registered studies
- Pazopanib HydrochlorideExisting use: Chromophobe renal cell carcinoma, Clear cell renal carcinoma, Collecting duct carcinoma and 4 more67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- CyclothiazideExisting use: Cardiovascular disease67.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Vincristine SulfateExisting use: Neoplasm67.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm67.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AmprenavirExisting use: HIV infection, Viral disease67.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- IndapamideExisting use: Cardiovascular disease, Congestive heart failure, Hypertension and 1 more67.3% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria66.9% AI-predicted activityagainst M. tuberculosis23 registered studies
- PerphenazineExisting use: Nausea and vomiting, Psychosis, Schizophrenia66.9% AI-predicted activityagainst M. tuberculosis34 registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more66.9% AI-predicted activityagainst M. tuberculosis14 registered studies
- Infigratinib PhosphateExisting use: Cancer, Cholangiocarcinoma, Intrahepatic cholangiocarcinoma and 1 more66.8% AI-predicted activityagainst M. tuberculosis2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC
NCT01562210 · start 2012-04
Registered record
- Registry ID
- NCT01562210
- Conditions
- NSCLC
- Interventions
- Olaparib; Cisplatin; Radiation
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-04
- Completion
- 2020-03-13
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNSCLCInterventionOlaparib; Cisplatin; RadiationPhasePhase 1Registry statusCompletedTrial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
NCT01296763 · start 2011-01
Registered record
- Registry ID
- NCT01296763
- Conditions
- Pancreatic Cancer
- Interventions
- Irinotecan; Cisplatin; Olaparib (for levels 1 and 5); Olaparib (for dose level 2); Mitomycin-C
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-01
- Completion
- 2016-02
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPancreatic CancerInterventionIrinotecan; Cisplatin; Olaparib (for levels 1 and 5); Olaparib (for dose level 2) +1 morePhasePhase 1Registry statusCompletedAZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
NCT01445418 · start 2008-05-12
Registered record
- Registry ID
- NCT01445418
- Conditions
- Breast Cancer; Ovarian Cancer
- Interventions
- AZ2281 + Carboplatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-05-12
- Completion
- 2019-10-18
- Enrolment
- 103
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Ovarian CancerInterventionAZ2281 + CarboplatinPhasePhase 1Registry statusCompletedAZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
NCT00535353 · start 2008-01-02
Registered record
- Registry ID
- NCT00535353
- Conditions
- Colorectal Cancer
- Interventions
- irinotecan hydrochloride; olaparib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-01-02
- Completion
- 2015-02-13
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventionirinotecan hydrochloride; olaparibPhasePhase 1Registry statusCompletedA Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
NCT00516373 · start 2005-07-11
Registered record
- Registry ID
- NCT00516373
- Conditions
- Ovarian Neoplasms; BRCA1 Protein; BRCA2 Protein
- Interventions
- KU-0059436 (AZD2281)(PARP inhibitor)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-07-11
- Completion
- 2023-04-26
- Enrolment
- 98
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOvarian Neoplasms; BRCA1 Protein; BRCA2 ProteinInterventionKU-0059436 (AZD2281)(PARP inhibitor)PhasePhase 1Registry statusCompleted